Covidien Runs Familiar But Different Plays to Build Vascular Franchise

Covidien Ltd. continues to build its vascular global business unit with the acquisition of peripheral leader ev3 Inc.

By agreeing to pay $2.6 billion to acquire endovascular player ev3 Inc., Covidien Ltd. emphatically made two points. [See Deal] First, Covidien – now three years removed from its spin out of Tyco International Ltd. – is demonstrating a familiar pattern of growing through acquisitions, as it did under Tyco a decade ago. [See Deal] Second, Warburg Pincus and Vertical Group made a good call 10 years ago in backing the creation of ev3 to target vascular markets outside the coronary, at least in the eyes of one of the principals who started the company.

In building through buying, Covidien is working with a familiar playbook. As Tyco Healthcare Group, the company grew into a...

More from Archive

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.